.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XD06_Efaproxiral.Efaproxiral .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XD06_Efaproxiral.Efaproxiral| name: | Efaproxiral | |
| ATC code: | L01XD06 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 330 | mg |
| volume of distribution: | 11.6 | L |
| clearance: | 2.35 | L/h |
| other parameters in model implementation | ||
Efaproxiral (RSR13) is an allosteric effector of hemoglobin, designed to decrease hemoglobin oxygen affinity and thereby enhance tissue oxygenation. It was primarily investigated as a radiosensitizer for treatment of hypoxic tumors, especially in patients with brain metastases. Efaproxiral is not an approved drug and its clinical development has been discontinued.
Parameters derived from published phase I study in adult cancer patients (n=43), both sexes, median age around 57 years, after intravenous administration.